Categories AlphaGraphs, Earnings, Technology
Earnings: Hewlett Packard Enterprise (HPE) Q4 earnings beat Street view
Information technology solutions provider Hewlett Packard Enterprise (NYSE: HPE) Tuesday reported higher earnings and revenues for the fourth quarter of 2022. The bottom line also exceeded analysts’ forecasts.
Fourth-quarter profit, excluding one-off items, moved up to $0.57 per share from $0.52 per share a year earlier and came in above consensus estimates. On a reported basis, it was a net loss of $304 million or $0.23 per share in the three-month period, compared to a profit of $2.55 billion or $1.91 per share in the same period of 2021.
Check this space to read management/analysts’ comments on Hewlett Packard’s Q4 2022 results
The tech firm’s revenues increased 7% annually to $7.9 billion in the fourth quarter, beating analysts’ estimates. The management also provided guidance for the first quarter and full year of 2023.
“HPE had an impressive fourth quarter, generating an outstanding performance across our key performance metrics. We are producing strong financial results as we meet new customer needs with the edge-to-cloud portfolio that only we can deliver,” said Hewlett Packard’s CEO Antonio Neri.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs